Rockefeller Capital Management
YMAB

Rockefeller Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Rockefeller Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-150
Closed -$5K – 2504
2019
Q4 		$5K Hold
150
– – ﹤0.01% 1797
2019
Q3 		$4K Hold
150
– – ﹤0.01% 1703
2019
Q2 		$3K Hold
150
– – ﹤0.01% 1522
2019
Q1 		$4K Buy
+150
New +$3.29K ﹤0.01% 1688

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Rockefeller Capital Management's YMAB Position: Q1 2020 in Review

Rockefeller Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2020, closing a stake of 150 shares — an estimated $5K sold.

Rockefeller Capital Management first reported a position in YMAB in Q1 2019 and held it in 4 quarters. The position peaked at $5K in Q4 2019. 80 funds tracked by Wall St. Rank hold YMAB as of Q1 2020.

  • Rockefeller Capital Management reported no remaining Y-mAbs Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Rockefeller Capital Management sold 150 Y-mAbs Therapeutics shares in Q1 2020, an estimated $5K.
  • Rockefeller Capital Management first reported a position in Y-mAbs Therapeutics in Q1 2019 and held it in 4 quarters.
  • Rockefeller Capital Management's Y-mAbs Therapeutics position peaked at $5K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2020.

Based on Rockefeller Capital Management's 13F filing for Q1 2020, filed 12 May 2020.